April 25 (Reuters) - Cigna (CI.N), opens new tab plans to make close copies of AbbVie's (ABBV.N), opens new tab blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday.
Boehringer Ingelheim’s 2023 was largely marked by the highly anticipated launch of its Cyltezo, the first interchangeable biosimilar to AbbVie’s Humira. But with sales disappointing, the company is now turning its attention to a deep late-stage pipeline that could bring 25 new treatments to market through 2030.
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s (ABBV.N), opens new tab blockbuster arthritis treatment Humira.
April 2 (Reuters) - Roivant Sciences' (ROIV.O), opens new tab experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's shares up nearly 8% on Tuesday.
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
Teva and Alvotech`s Humira biosimilar finally snags FDA approval
Alvotech`s Biologic Simlandi (adalimumab) Receives Approval in the U.S.
Organon Announces HADLIMA Has Been Selected by the US Department of VA
Organon's Humira biosimilar gets exclusive spot on VA formulary
Real Humira competition may not arrive until 2026, AbbVie execs tell investors